Induced pluripotent cell-derived oligodendrocyte progenitor cells for the treatment of myelin disorders
The present disclosure relates to a preparation of CD140a/PDGFRα positive cells that comprises oligodendrocyte progenitor cells co-expressing OLIG2 and CD140a/PDGFRα. The preparation of cells is derived from pluripotent cells that were derived from skin cells, fibroblasts, umbilical cord blood, peripheral blood, bone marrow, or other somatic cells. The cell preparation has an in vivo myelination efficiency that is equal to or greater than the in vivo myelination efficiency of a preparation of A2B5+/PSA-NCAM− sorted fetal human tissue derived oligodendrocyte progenitor cells. Methods of making, isolating and using the disclosed cell preparation are also described.
1. A population of cells derived from a preparation of human pluripotent stem cells, wherein greater than 30% of said population comprises human oligodendrocyte progenitor cells, wherein said human oligodendrocyte progenitor cells in the population co-express oligodendrocyte transcription factor 2 (OLIG2), CD140a/platelet derived growth factor receptor α (PDGFR α), and SOX10, and wherein said population of cells contains less than 4% of MAP2 immunoreactive neuron,
wherein said human oligodendrocyte progenitor cells are capable of differentiating into astrocytes as well as oligodendrocytes, and
wherein said population contains more PDGFR α + cells than O4 + cells.
2. The population of claim 1 , wherein the oligodendrocyte progenitor cells of the population further express CD9.
3. The population of claim 1 , wherein said population contains less than 1% residual pluripotent cells.
4. The population of claim 1 , wherein at least 95% of the population comprises oligodendrocyte progenitor cells.
5. The population of claim 1 , wherein said population has an in vivo myelination efficiency that is greater than the in vivo myelination efficiency of a preparation of A2B5+/PSA-NCAM− sorted fetal human tissue derived oligodendrocyte progenitor cells.
6. The population of claim 1 , wherein said population is capable of achieving an in vivo myelination density upon engraftment which is greater than that achievable with a population of A2B5+/PSA-NCAM− sorted fetal human tissue derived oligodendrocyte progenitor cells.
7. The population of claim 1 , wherein said population is capable upon engraftment of achieving improved survival in a myelination deficient mammal compared to that achievable with a preparation of A2B5+/PSA-NCAM− sorted fetal human tissue derived oligodendrocyte progenitor cells.
8. The population of claim 1 , wherein said population of cells contains less than 3% of MAP2 immunoreactive neurons.
9. The population of claim 1 , wherein said population of cells contains less than 2% of MAP2 immunoreactive neurons.
10. The population of claim 1 , wherein said population of cells contains less than 1% of MAP2 immunoreactive neurons.
11. The population of claim 1 , wherein the preparation of human pluripotent stem cells are human embryonic stem cells.
12. The population of claim 1 , wherein the preparation of human pluripotent stem cells are induced pluripotent stem cells (iPSCs).
13. A population of cells derived from a preparation of human pluripotent stem cells, wherein at least 95% of said population comprises human oligodendrocyte progenitor cells, wherein said human oligodendrocyte progenitor cells in the population co-express oligodendrocyte transcription factor 2 (OLIG2), CD140a/platelet derived growth factor receptor α (PDGFRα), and SOX10, and wherein said population of cells contains less than 4% of MAP2 immunoreactive neurons,
wherein said human oligodendrocyte progenitor cells are capable of differentiating into astrocytes as well as oligodendrocytes, and
wherein said population contains more PDGFR α + cells than O4 + cells.
14. The population of claim 13 , wherein the preparation of human pluripotent stem cells are human embryonic stem cells.
15. The population of claim 13 , wherein the oligodendrocyte progenitor cells of the population further express CD9.
16. The population of claim 13 , wherein said population contains less than 1% residual pluripotent cells.
17. The population of claim 13 , wherein said population of cells contains less than 3% of MAP2 immunoreactive neurons.
18. The population of claim 13 , wherein said population of cells contains less than 2% of MAP2 immunoreactive neurons.
19. The population of claim 13 , wherein said population of cells contains less than 1% of MAP2 immunoreactive neurons.
20. The population of claim 13 , wherein the preparation of human pluripotent stem cells are induced pluripotent stem cells (iPSCs).